Protalix BioTherapeutics, Inc. (PLX) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 80.57M; Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 80.57M | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 80.57M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-06-30 | 80.57M | (m) | (m) |
| 2026-03-31 | 80.57M | (m) | (m) |
| 2025-12-31 | 80.57M | (m) | (m) |
| 2025-09-30 | 80.42M | (m) | (m) |
| 2025-06-30 | 79.73M | (m) | (m) |
| 2025-03-31 | 79.61M | (m) | (m) |
| 2024-12-31 | 78.03M | (m) | (m) |
| 2024-09-30 | 73.63M | (m) | (m) |
| 2024-06-30 | 73.54M | (m) | (m) |
| 2024-03-31 | 73.32M | (m) | (m) |
| 2023-12-31 | 73.05M | (m) | (m) |
| 2023-09-30 | 72.95M | (m) | (m) |
| 2023-06-30 | 71.58M | (m) | (m) |
| 2023-03-31 | 65.41M | 0.00 | 0.00% |
| 2022-12-31 | 57.35M | (m) | (m) |
| 2022-09-30 | 50.67M | (m) | (m) |
| 2022-06-30 | 49.75M | (m) | (m) |
| 2022-03-31 | 47.06M | (m) | (m) |
| 2021-12-31 | 46.32M | (m) | (m) |
| 2021-09-30 | 45.56M | (m) | (m) |
| 2021-06-30 | 45.56M | (m) | (m) |
| 2021-03-31 | 45.38M | 0.00 | 0.00% |
| 2020-12-31 | 45.38M | (m) | (m) |
| 2020-09-30 | 33.34M | (m) | (m) |
| 2020-06-30 | 32.44M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |